ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Cardiac Manifestations of Mycoplasma pneumoniae Infections: A Cohort Study 2007-2024.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Respiratory Pathogen to Systemic Threat: RethinkingMicroorganisms · 2026Review
- Age-related heterogeneity in diagnosis-coded pediatricFrontiers in public health · 2026Article
- Inflammatory Mediation of the Association Between Latent Clinical Phenotypes and Multidimensional Outcomes in Pediatric Community-Acquired Pneumonia.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile Mycoplasma pneumoniae (MP) infections typically present as a respiratory disease, extrapulmonary manifestations are well-documented. Historically, cardiac involvement has been considered uncommon (1%-2%); however, recent observations suggest higher rates, especially in MP ICU patients. This study aims to characterize the prevalence, clinical spectrum, and outcomes of hospitalized patients with MP and cardiac manifestations.
methodsWe conducted a cohort study at Hadassah Medical Center, Jerusalem, Israel, including all inpatients with a positive PCR for MP from 2007 to mid-2024. Cardiac involvement included congestive heart failure (CHF), arrhythmias, acute coronary syndrome (ACS), peri/myocarditis, and isolated troponin elevation.
resultsOf 1305 MP-positive patients (mean age 33.4 years), 152 (11.6%) were found to have cardiac involvement-17% among adult patients and 4.9% among children (P < .001). In adults, CHF and arrhythmias were most common (each 34.7%), followed by ACS (10.5%), peri/myocarditis (15.3%), and isolated troponinemia (9.7%). ICU admission occurred in 50% of adults with cardiac involvement and was significantly higher in arrhythmias and peri/myocarditis groups. In-hospital mortality among adults was high at 22.6%. Predictors of mortality included ICU admission (aOR 7.76; CI: 2.78-21.66), older age (aOR per year increase: 1.03; CI: 1.01-1.06), and primary diagnosis other than MP (aOR 3.57; CI: 1.34-9.51). Pediatric cardiac involvement primarily presented as arrhythmia (42.9%).
conclusionsCardiac involvement in hospitalized MP-infected adults is more common than previously recognized (17%) and carries substantial morbidity and mortality risks. Early evaluation for cardiac complications is crucial in MP-infected hospitalized patients presenting with severe illness or unexplained cardiac symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.